{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"5"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"}],"units":"Participants"}],"description":"An adverse events is defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occur after participant's signed informed consent has been obtained. A SAE is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 BID as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"NUMBER","populationDescription":"The safety set included all participants who had received at least one dose of LTT462.","reportingStatus":"POSTED","timeFrame":"Up to 2.8 years","title":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}